About the Authors
- Julie Steinestel
-
Affiliation Department of Urology, University of Ulm, Ulm, Germany
- Marcus V. Cronauer
-
Affiliation Department of Urology, University of Ulm, Ulm, Germany
- Johannes Müller
-
Affiliation Department of Urology, University of Ulm, Ulm, Germany
- Andreas Al Ghazal
-
Affiliation Department of Urology, University of Ulm, Ulm, Germany
- Peter Skowronek
-
Affiliation Gemeinschaftspraxis for Pathology Augsburg, Augsburg, Germany
- Annette Arndt
-
Affiliation Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Ulm, Germany
- Klaus Kraft
-
Affiliation Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Ulm, Germany
- Mark Schrader
-
Affiliation Department of Urology, University of Ulm, Ulm, Germany
- Andres J. Schrader
-
Affiliation Department of Urology, University of Ulm, Ulm, Germany
- Konrad Steinestel
-
* E-mail: konrad@steinestel.com
Affiliations Bundeswehr Institute of Radiobiology, Munich, Germany, Institute of Pathology, University of Ulm, Ulm, Germany
Competing Interests
The authors read the journal's policy and have the following conflicts: Prof. AJ Schrader receives compensation as a consultant for Bayer Healthcare AG, which manufactures Sorafenib (Nexavar®) for clinical application. All other authors have declared that no competing interests exist. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JS AS KS. Performed the experiments: JS JM AAG PS AA KS. Analyzed the data: JS MC PS AA KK KS. Contributed reagents/materials/analysis tools: MC AA AS MS KK. Wrote the paper: JS AS KS.